GO
Loading...

Enter multiple symbols separated by commas

Merck & Co Inc

More

  • Early movers: BP, F, AAPL, BMY, COH, PFE & more Tuesday, 28 Apr 2015 | 8:01 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • All eyes on Pfizer and Merck earnings   Tuesday, 28 Apr 2015 | 5:30 AM ET
    All eyes on Pfizer and Merck earnings

    Ranjith Gopinathan, program manager of life sciences and healthcare practice at Frost & Sullivan, shares his forecasts for Pfizer and Merck earnings.

  • Health care, Tesla top Halftime's trades to go Monday, 27 Apr 2015 | 2:49 PM ET

    The "Halftime Report" traders give their trades for the second half.

  • *FDA cites concerns over late-stage study design, results. April 27- U.S. Food and Drug Administration staff reviewers said an accelerated review of drugmaker Amgen Inc's skin cancer immunotherapy cannot be considered at this time, citing concerns over the design and results of a key study. T-Vec represents a new class of agent for the treatment of metastatic...

  • Why the S&P could break out this week Monday, 27 Apr 2015 | 7:12 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • Bulls sniffing out an S&P breakout Monday, 27 Apr 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange.

    As the Fed meets and earnings news rains down, the big question in the week ahead is whether the S&P 500 can manage a break out.

  • NEW YORK, April 24- Healthcare companies on a seven-year tear have been top performers so far in 2015, helping to push broad stock indexes to record levels, but traders are now looking to protect themselves from a selloff as they await major earnings reports in the sector. Companies reporting first-quarter earnings next week include Bristol-Meyers Squibb Co,...

  • LONDON, April 24- European regulators have recommended approval of Bristol-Myers Squibb's Opdivo, paving the way for it to become the first of a closely watched group of immune system-boosting cancer medicines to go on sale in Europe. It competes with Merck& Co's Keytruda, which is also on the market in the United States but not in Europe. Although Keytruda is...

  • April 23- A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body's immune system to kill cancer cells. The partnership between AstraZeneca's research and development arm MedImmune and Juno is the latest collaboration between companies intent on developing a new class of drugs known as...

  • Tekmira Ebola drug succeeds in small monkey study Wednesday, 22 Apr 2015 | 1:00 PM ET

    NEW YORK, April 22- An experimental Ebola drug from Tekmira Pharmaceuticals Corp cured all three monkeys intentionally infected with the virus, scientists reported on Wednesday, the first such success against the strain of Ebola in West Africa's 2014-2015 outbreak. Although other experimental treatments appeared to help Ebola patients last year,...

  • April 17- A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications. AstraZeneca Plc, Pfizer Inc and other drugmakers are developing their...

  • Biotech investors brace for updates on key drugs Friday, 17 Apr 2015 | 1:44 PM ET
    Lab technician handling test tubes

    Biotech investors are going to be busy with new data on Alzheimer's drugs, cancer and genetic disorders on the way. Here's what analysts are watching.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed mildly lower as stocks struggled to hold gains from higher oil prices, amid investor focus on earnings.

  • Big pharma M&A may keep booming, CEOs say Thursday, 16 Apr 2015 | 3:44 PM ET
    Generic copies of Merck & Co.'s cholesterol pill Zocor and Pfizer Inc.'s Zoloft antidepressant.

    For Pfizer and Merck, two big names that have ridden the merger wave, buying up more business is a possibility, their CEOs said.

  • Former Teva CEO's new gig at Ovid Therapeutics Thursday, 16 Apr 2015 | 6:10 AM ET

    After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.

  • LONDON, April 15- Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move-- quite literally. Chief Executive Pascal Soriot is making AstraZeneca more nimble as hopes build for its cancer pipeline, but he still has his work cut out to keep 2015 earnings above the floor needed to protect his...

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza and Takeda Pharmaceutical Co.' s rival product Nesina should carry information about the risk of heart failure, an advisory committee to the U.S. Food and Drug Administration said on Tuesday. The panel reviewed safety data on AstraZeneca's Onglyza and Takeda's Nesina. The studies were requested by...

  • A preliminary FDA review of Nesina, or alogliptin, showed a numerical increase in heart failure hospitalizations but not a statistically significant increase. Even so, some analysts expect the FDA to treat all drugs in the class the same way. "We believe the FDA will likely view the risk as likely to be a class effect and apply changes to all approved drugs in the...

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza should include new safety information about the risk of heart failure, a U.S. Food and Drug Administration advisory panel concluded on Tuesday. The FDA is not obliged to follow the advice of its advisory panels but typically does so. A preliminary FDA review of the drug published on Friday noted an...

  • Traders work the floor of the New York Stock Exchange.

    U.S. stocks closed higher, with the Dow above 18,000 for the first time in April as investors looked ahead to the official start of earnings season.